Drugs / Etalanetug
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04231513 | Dec 2019 → Mar 2023 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04971733 | Jun 2021 → May 2024 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06602258 | Sep 2024 → Dec 2026 expected | Alzheimer disease | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05269394 | Dec 2021 → Apr 2028 expected | early-onset autosomal dominant Alzheimer disease | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01760005 | Dec 2012 → Apr 2028 expected | familial Alzheimer disease | Washington University School of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etalanetug | “Etalanetug (E2814) is designed to delay the clinical progression of Alzheimer's disease (AD) by binding to the microtubule binding region (MTBR) of tau implicated in seeding...” PMID 41964075 ↗ Apr 2026 |
| Known as | E2814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04231513 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068452 ↗ |
| Route | Intravenous | “Administered intravenously in a blinded fashion” NCT01760005 ↗ |